medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 4

<< Back Next >>

Med Int Mex 2020; 36 (4)

Dermatomyositis/polymyositis

Mercado U, Yocupicio FM, Mercado H

Language: Spanish
References: 19
Page: 502-508
PDF size: 236.84 Kb.


ABSTRACT

Objective: To analyze a case series of idiopathic dermatomyositis/polymyositis according to the original criteria of Bohan and Peter.
Material and Method: A prospective study was done analyzing patients of the General Hospital of Mexicali from 2010 to 2018, who had combination of muscle weakness, muscle enzymes elevation, myositis, myopatic pattern by electromyography and skin disease. Muscle weakness, levels of muscle enzymes, muscle biopsies, skin manifestations, electromyographic findings, tumor markers, anti-virus antibodies, radiological studies and specific antibodies for myositis were reviewed. According to the criteria gathered, the diagnosis was defined and probable.
Results: Twenty-three cases were identified during the study period. Ninety percent of subjects with dermatomyositis had definite disease and 91% probable polymyositis. There were three cases with cancer, three cases of juvenile dermatomyositis/polymyositis and one case of polymyositis associated with rheumatoid arthritis. In three cases the creatine kinase enzyme was normal. One case of polymyositis and pulmonary fibrosis was positive for anti-Jo-1. Muscle biopsy showed myositis in 22 cases and myopathic pattern by electromyography in one case.
Conclusions: The classification of Bohan and Peter is still useful in adults and children. The new classification of myositis del ACR*EULAR is provisional and controversial and includes new types of inflammatory myopathy.


REFERENCES

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis. New Engl J Med 1975;292:344-7. DOI: 10.1056/ NEJM197502132920706

  2. Bohan A, Peter JB. Polymyositis and dermatomyositis. New Engl J Med 1975;292:403-7. doi: 10.1056/ NEJM197502202920807

  3. Bohan A, Peter JB, Bowman RL, Pearson CM. Computerassisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56:255-286. doi: 10.1097/00005792-197707000-00001

  4. Leclair V, Lundberg IE. New myositis classification criteria- What we have learned since Bohan and Peter. Curr Rheumatol Rep 2018; 20 :1-16. doi: 10.1007/s11926-018-0726-4

  5. Chatter S, Prayson R, Farver C. Antisynthetase syndrome. Not just an inflammatory myopathy. Cleve Clin J Med 2013; 80: 655-666. doi: 10.3949/ccjm.80a.12171

  6. Vulsteke JB, De Langhe, E , Claeys KG, Dillaerts D, Poesen K, Lenaerts J y cols. Detection of myositis-specific antibodies. Ann Rheum Dis 2019; 78: 1-4. http://dx.doi.org/10.1136/ annrheumdis-2017-212915

  7. Rauchaudhuri SP, Mitra A. Polymyositis and dermatomyositis: disease spectrum and classification. Indian J Dermatol 2012; 57: 366-370. doi: 10.4103/0019-5154.100477

  8. Lundberg IE, de Viser M, Werth BP. Classification of myositis. Nat Rev Rheumatol 2018; 5: 269-278. doi: 10.1038/ nrrheum.2018.41

  9. GhjBrouwer R, Hegstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116-123. doi: 10.1136/ard.60.2.116

  10. Sultan SM, Isenberg DA. Re-classifying myositis. 30 years on from Bohan and Peter. Rheumatology 2010; 49: 831-833. https://doi.org/10.1093/rheumatology/kep355

  11. Di Muzio A, Bonetti B, Capasso M, Panzen L, Pizzigallo E, Rizzuto N y col. Hepatitis C virus infection and myositis: a virus localization study. Neuromusc Dis 2003; 13: 68-71. doi: 10.1016/s0960-8966(02)00184-0

  12. Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1986; 30: 213-7. https://doi.org/10.1002/art.1780300212

  13. Zuber M, John S, Pfreundschuh M, Gause A. A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum 1996; 39: 1419-1422. doi: 10.1002/art.1780390822

  14. Uruha A, Noguchi S, Hayashi YK, Tsburaya RS, Yonekawa T, Nonaka I et al. Hepatitis C virus infection in inclusion body myositis: A case-control study. Neurology 2016; 86: 211-7. doi: 10.1212/WNL.0000000000002291

  15. Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology 2006; 45: 18-21. doi: 10.1093/ rheumatology/kel311

  16. Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general populationbased- study. Rheumatology (Oxford) 2016; 5: 461-469. doi: 10.1093/rheumatology/kev336

  17. Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Turner-Warwick M, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 1984; 289: 151-2. doi: 10.1136/bmj.289.6438.151

  18. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983; 304: 177-9. doi: 10.1038/304177a0

  19. Lundberg IE, Tjarnlund A, Bottal M, European League Against Rheumatism/American College of Rheumatology classification for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 2017: 1955-64. doi: 10.1136/annrheumdis- 2017-211468.




2020     |     www.medigraphic.com